Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis research hub

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

This study is looking into a new medicine called pegozafermin for people with a liver condition called MASH, which includes scarring (fibrosis). It compares pegozafermin to a dummy medicine to see if it's safe and helps improve the liver. We want to find better ways to treat this condition.